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Introduction
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian
target of rapamycin (mTOR) pathway is a critical signaling
pathway downstream of the growth factor receptor tyrosine
kinases that regulates cell growth and survival. mTOR func-
tions depend on the associated protein RAPTOR in the
mTORC1 complex or RICTOR in the mTORC2 complex. Of
the two complexes, mTORC1 has been the most extensively
investigated as an anti-tumor target, because of its modula-
tion by rapamycin and rapamycin analogs, such as everolimus
and temsirolimus.
Specifically, mTORC1 serves as a molecular sensor to
control protein synthesis via regulation of two separate
downstream targets: the 40S ribosomal protein S6 kinase
(p70S6K) and the eukaryotic initiation factor 4E binding
protein-1 [1]. Upon activation, p70S6K directly phosphory-
lates the 40S ribosomal protein S6, which correlates with
enhanced translation of transcripts with a 5′-terminal oligo-
pyrimidine tract, such as elongation factor-1 alpha and
ribosomal proteins [2]. mTOR phosphorylation of the trans-
lational repressor 4E binding protein-1 results in its disso-
ciation from eukaryotic initiation factor 4E, and in the initiation
of cap-dependent translation of transcripts with long, highly
structured 5′-untranslated regions, such as cyclin D1 and c-
myc [3]. By regulating the components of the protein
synthetic machinery and cap-dependent translation, both of
the mTOR-dependent phosphorylation events therefore lead
to translation of proteins required for cell cycle transit.
Mammalian target of rapamycin and breast
cancer
The PI3K/Akt/mTOR pathway can be activated in breast
cancer by a number of mechanisms. These mechanisms
include amplification of the PI3K p110 alpha catalytic subunit
or Akt; mutation of the PI3K p85 beta regulatory subunit or
p70S6K; loss of the phosphatase and tensin homologue
deleted on chromosome 10 (PTEN), which inhibits PI3K-
dependent activation of Akt and terminates PI3K-mediated
signalling; and, more often, sustained activation or
overexpression of cell surface growth factor receptors, such
as those of the human epidermal growth factor receptor
family – HER1 or EGFR and HER2 or insulin-like growth
factor-1 receptor (IGF1R) (reviewed in [4]).
The presence of compensatory pathways is not surprising in
such a complicated network. One negative feedback loop
involves p70S6K, insulin-like growth factor receptor substrate
1 and IGF1R proteins. Insulin-like growth factor receptor
substrate 1 is a docking protein for the IGF1R and serves to
activate the regulatory subunit of PI3K. Phosphorylation of
p70S6K by activated mTOR leads to the degradation of
insulin-like growth factor receptor substrate 1, and conse-
quently to suppression of PI3K/Akt signaling. The inhibition of
p70S6K through mTOR-targeted agents therefore interrupts
this negative feedback, resulting in sustained activation of the
IGF1R signaling [5]. Taking advantage from this compen-
satory pathway, combined therapies designed to block both
mTOR and IGF1R pathways or to block both mTOR and
PI3K/Akt pathways may provide a synergistic effect [6].
Other studies have demonstrated that inhibition of mTORC1
leads to mitogen-activated protein kinase pathway activation
through a PI3K-dependent feedback loop [7], and that
prolonged exposure to rapamycin may lead to Akt inhibition
through depletion of mTORC2 (mTOR-rictor complex), which
normally sits upstream and activates Akt [8].
Mammalian target of rapamycin blockade
Consistent with its critical role in cell growth and survival, the
high rate of dysregulation in breast cancer [9] and in the
onset of resistance to conventional anti-cancer strategies –
including anti-HER2 and endocrine therapy [4] – PI3K/Akt/
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mTOR cascade has soon become an attractive target for
drug development. Clinical trials are currently underway with
PI3K, Akt and mTOR inhibitors. NVP-BEZ235 belongs to the
class of imidazoquinolines, and potently and reversibly
inhibits the PI3K catalytic activity by competing at its ATP-
binding site. Other agents include the dual PI3K/mTOR
inhibitor XL765, and the pure PI3K inhibitor XL147.
Clinical studies
Initial data from phase I studies suggest that these com-
pounds are safe and that PI3K signaling inhibition is
achievable (reviewed in [10]). The mTOR inhibitors temsiro-
limus and everolimus are further ahead in development either
as a single agent or in combination with endocrine therapy. In
the case of everolimus, a series of well-conducted pharmaco-
kinetic/pharmacodynamic studies that analyzed mTOR
inhibition in tumors as well as in surrogate tissues [11] led to
the identification of a dose of 10 mg/day as optimal for further
clinical development [12,13]. In a subsequent phase II,
double-blind, randomized study of everolimus in combination
with letrozole versus placebo and letrozole in the neoadjuvant
setting [13], the combination arm proved to be superior over
letrozole and placebo with a higher significant response rate
(68% vs. 59%) [13]. This study incorporated carefully con-
ducted prestudy and onstudy tumor biopsies and pharmaco-
dynamic studies, and demonstrated a near doubling of the
cell cycle response rate by decreases in Ki67 in the
everolimus group – the patients with a PI3K mutation being
those with the greatest benefit. This is potentially important,
since a Ki67 drop in the neoadjuvant setting has been
recently demonstrated to correlate with long-term outcome.
The initial phase II study of letrozole alone or in combination
with the other mTOR inhibitor temsirolimus in metastatic
breast cancer patients showed benefit from the combination
in terms of median progression-free survival (13.2 months vs.
11.6 months) [14]. The successive large, phase III, rando-
mized trial of letrozole alone or in combination with temsiro-
limus in 992 postmenopausal women was terminated early,
however, after an interim analysis demonstrated a lack of
benefit from the combination [15]. This negative result is not
ascribed to the lack of efficacy of this combinatorial strategy,
but rather to the suboptimal inhibition of the mTOR pathway
with the dose of temsirolimus implemented (30% of patients
discontinued treatment), to the study population (phase II
was realized in heavily pretreated and endocrine-resistant
patients, whereas phase III was up front), and to the
unselected patient population, with the inability to identify
patients in whom the tumors exhibit dependence on
PI3K/mTOR activation.
In addition, as mentioned above, evidence exists that
feedback mechanisms may overcome the effects of mTOR
inhibition. An understanding of compensatory pathways is
therefore also critical to optimize targeted therapies. Based
on preclinical models, dual inhibition of both IGF1R – with
either monoclonal antibodies or tyrosine kinase inhibitors –
and mTOR results in a superior antiproliferative effect over
each single strategy [5], and this combination is now being
explored in phase I/II trials in patients with breast cancer.
Another area of intensive research is the combination of
inhibitors of HER2 and mTOR inhibition. The rationale for this
combination is the interaction of HER2 and the PI3K
pathway, which ultimately funnels into the mTOR pathway.
Based on promising early results, one phase II study is
examining the safety, tolerability and response rate of the
combination of trastuzumab and everolimus in patients with
HER2-overexpressing breast cancer with trastuzumab-
refractory metastatic disease [16].
Conclusions
The PI3K/Akt/mTOR pathway plays a critical role in breast
cancer development and resistance to traditional anti-tumor
strategy including endocrine-targeted and HER2-targeted
agents. Treatment with mTOR inhibitors has modest activity
in breast cancer patients with a response rate of 10%. A
combined approach has produced promising results in
pretreated postmenopausal breast cancer patients and in
patients harboring PI3K mutations treated with endocrine
therapy. Studies are ongoing to assess the efficacy of mTOR
inhibitors with chemotherapy and HER2-targeted agents to
overcome resistance to the anti-Her2 monoclonal antibody
trastuzumab. Consistent with a mechanistic-based approach,
studies are currently ongoing with mTOR and IGF1R
inhibitors and with mTOR and PI3K inhibitors to prevent the
negative feedback loops secondary to mTOR inhibition.
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